Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
| dc.contributor.author | Bamias, A. | |
| dc.contributor.author | De Santis, M. | |
| dc.contributor.author | Arranz, J. A. | |
| dc.contributor.author | Grande, E. | |
| dc.contributor.author | Galsky, M. D. | |
| dc.contributor.author | Kikuchi, E. | |
| dc.contributor.author | Park, S. H. | |
| dc.date.accessioned | 2025-05-10T19:48:31Z | |
| dc.date.issued | 2020 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description | ESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORK | |
| dc.description.abstract | [No abstract available] | |
| dc.description.sponsorship | European Soc Med Oncol | |
| dc.description.sponsorship | F. Hoffmann-La Roche, Ltd. | |
| dc.description.sponsorship | F. Hoffmann-La Roche, Ltd. | |
| dc.identifier.doi | 10.1016/j.annonc.2020.08.770 | |
| dc.identifier.endpage | S552 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | S551 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.08.770 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/11729 | |
| dc.identifier.volume | 31 | |
| dc.identifier.wos | WOS:000573469100693 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Annals of Oncology | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.title | Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) | |
| dc.type | Conference Object |
Dosyalar
Orijinal paket
1 - 1 / 1










